Retatrutide 10 mg research-grade lyophilized peptide powder in a glass vial. Retatrutide (LY3437943), marketed here as Reta-Solution, is an investigational multi-receptor peptide agonist that targets the receptors for GIP, GLP-1 and glucagon, and is used in experimental models of obesity, glycemic control and metabolic regulation.
Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
99%+ (HPLC, third-party tested)
Form
Lyophilized peptide powder
Content
10 mg Retatrutide per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C221 H342 N46 O68
Molecular weight
~4731.4 g·mol⁻¹
Sequence
Multidomain incretin/glucagon analog (GIP/GLP-1/glucagon triple agonist) peptide backbone with C20 fatty diacid and γGlu–(AEEA)2 side chain for extended PK (Retatrutide, LY3437943).
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC). For a compatible research-only solvent, see
Bacteriostatic water – 10 ml .
Research Overview
Retatrutide is a next-generation multi-agonist peptide that engages GIP, GLP-1 and glucagon receptors simultaneously. It is used in laboratory and preclinical models to study integrated control of body weight, glucose homeostasis and whole-body energy balance, without implying any therapeutic or clinical use.
Primary Research Areas
-
Triple GIP/GLP-1/glucagon receptor agonism: Mechanistic studies dissecting receptor pharmacology, biased signaling and downstream pathways triggered by combined incretin and glucagon receptor activation.
-
Obesity & body-weight regulation models: In vivo models exploring changes in body weight, adiposity, food intake and energy expenditure under Retatrutide-driven multi-agonist signaling.
-
Glycemic control & metabolic health: Research focused on glucose tolerance, insulin dynamics, hepatic glucose output and broader metabolic homeostasis in preclinical systems.
